SCHEMBL6033260

SCHEMBL6033260

CC(C)(C)OC(=O)NC(C)(C)c1ccc(-c2nc(Nc3cc(F)c(F)c(F)c3)ncc2C#N)cc1

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.47
CDK1 P06493 16/20 0.47
SYK P43405 1/20 0.39
EGLN2 Q96KS0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6033863 0.92 KDR (0.49) KDRCDK1SYK
SCHEMBL6034230 0.92 KDR (0.48) KDRCDK1SYK
SCHEMBL6033883 0.91 KDR (0.47) KDRCDK1SYK
SCHEMBL6033857 0.89 KDR (0.53) KDRCDK1
SCHEMBL6034167 0.88 KDR (0.48) KDRCDK1
SCHEMBL6034473 0.88 KDR (0.49) KDRCDK1SYK
SCHEMBL6033942 0.88 KDR (0.46) KDRCDK1
SCHEMBL6033554 0.87 KDR (0.59) KDRCDK1
SCHEMBL6034105 0.87 PLK1 (0.47) KDRCDK1
SCHEMBL6034030 0.86 KDR (0.42) KDRCDK1EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1187816-B1 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES CELLTECH R&D LTD (GB) 2006-12-20 EP disclosed
US-20040180914-A1 5-Cyano-2-aminopyrimidine derivatives CELLTECH R&D LIMTIED 2004-09-16 US disclosed
US-6579983-B1 Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase CELLTECH R&D LIMITED (GB) 2003-06-17 US disclosed
US-20020147339-A1 5-cyano-2-aminopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2002-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180914-A1 5-Cyano-2-aminopyrimidine derivatives FLT1, FGFR1, KDR KDR 3/4885CDK1 58/4885SYK 320/4885
US-20020147339-A1 5-cyano-2-aminopyrimidine derivatives FLT1, FGFR1, KDR KDR 3/4885CDK1 59/4885SYK 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.